Human Serum for ATMP Manufacturing: GMP Requirements, Donor Screening and Lot Qualification
ATMP and cell therapy manufacturing increasingly demands xeno-free, human-derived raw materials. Human serum — when correctly qualified — meets that requirement. This guide covers what the EU regulatory framework requires, what to look for in a supplier, and how to qualify a lot for GMP use.
Why ATMP Manufacturers Are Moving Away from FBS
The shift from FBS to human-derived supplements in cell therapy manufacturing is no longer just a scientific preference — it is a regulatory direction. EMA’s guideline on advanced therapy medicinal products (Guideline on human cell-based medicinal products, EMA/CHMP/410869/2008) and the current EU GMP Annex 2 for ATMPs both encourage the elimination of animal-derived materials from manufacturing processes where technically feasible, citing risks of xenogeneic contamination, immune reactions in recipients, and supply chain inconsistency.
For many ATMP applications — T-cell expansion, CAR-T manufacturing, MSC culture, NK cell production — human serum or human platelet lysate (hPL) can replace FBS at equivalent or superior cell yield and phenotype, while satisfying the xeno-free requirement that regulators and clinical sponsors increasingly expect in IND/IMPD submissions.
What Human Serum Offers in ATMP Manufacturing
| Parameter | FBS | Human Serum (AB type) |
|---|---|---|
| Species origin | Bovine — xenogeneic | Human — species-matched |
| Xeno-free status | No | Yes |
| ABO antibody interference | Not applicable | Absent in AB type (no anti-A, anti-B) |
| T-cell / NK expansion support | Suboptimal — xenogeneic immune activation risk | Optimal — physiological context for human immune cells |
| Regulatory acceptance (ATMP/GMP) | Discouraged where alternatives exist | Supported — aligns with xeno-free guidance |
| Viral safety testing | Bovine virus panel required | Human donor screening: HIV, HCV, HBV, syphilis, NAT |
| Lot-to-lot consistency | Variable — biological origin | Improved with pooled multi-donor lots (≥20 donors) |
GMP Requirements for Human Serum as a Raw Material
Donor screening and viral safety
Human serum used in GMP manufacturing must originate from donors screened according to the EU Blood Directive (2002/98/EC and technical Directives 2004/33/EC, 2005/61/EC, 2005/62/EC). Mandatory screening includes serological and NAT (nucleic acid testing) for HIV-1/2, HCV, HBV, and syphilis. The supplier must provide documented evidence of donor screening per lot, not just a blanket statement.
Certificate of Analysis — minimum contents for ATMP use
- Lot number, collection date, and processing date
- Donor pool composition (number of donors, blood group where applicable)
- Viral screening results (HIV, HCV, HBV, syphilis) — per lot, not per process
- Sterility result (USP <71> or Ph. Eur. 2.6.1 method)
- Mycoplasma test result
- Endotoxin (LAL) — typically <5 EU/mL or <1 EU/mL for critical applications
- Total protein concentration
- Haemoglobin content
- Country of origin and blood collection centre identity
Blood type: why AB serum is the only viable choice for ATMP
Human serum from blood type AB donors contains no anti-A or anti-B antibodies. This is essential for ATMP manufacturing: any serum containing ABO antibodies will react with cell surface antigens on non-matched donor cells, causing complement-mediated cytotoxicity. AB serum is the universal format — it is compatible with cells from donors of any blood type, which is a prerequisite for allogeneic ATMP manufacturing platforms.
Heat inactivation and other processing treatments
Heat inactivation (56 °C, 30 min) destroys complement activity, which is often specified for T-cell and NK cell expansion protocols where residual complement could impair cell viability. Gamma-irradiated human serum provides an additional viral safety margin and is required in some sponsor protocols. Both treatments must be documented in the CoA with process parameters and acceptance criteria.
TSE / prion safety documentation
While human serum does not carry the same TSE risk profile as bovine-derived materials, the Regulatory Master File (dossier) for your ATMP product will require a risk assessment for all human-derived raw materials covering variant CJD (vCJD). Your supplier must provide a TSE/BSE declaration and, where applicable, documentation of donor selection criteria that exclude individuals from vCJD risk populations (EMA/410/01 Rev. 3 applies).
Lot Qualification Workflow for GMP Human Serum
From supplier CoA to approved GMP lot
- Obtain full supplier documentation package: CoA, CoO, donor screening records, TSE declaration, sterility certificate
- Review supplier qualification status — ISO 13485 certification or equivalent quality management system for medical-grade biological materials
- Receive a small evaluation volume (50–200 mL); run incoming QC: visual inspection, pH, sterility, endotoxin (LAL), mycoplasma PCR
- Run cell-based performance qualification: expand your target cell type (T cells, NK cells, MSCs) in media supplemented with test lot vs. reference lot; assess viability, expansion fold, and phenotype markers
- For allogeneic ATMP: confirm AB type and absence of anti-A/anti-B antibodies via agglutination test if not specified by supplier
- Review results against your internal acceptance specification; create lot qualification report for the batch record
- Reserve the bulk lot; document lot number and reserved quantity in your raw material inventory system
GMP-Compatible Human Serum AB — EU Origin, Full Documentation
Human serum Type AB (off-the-clot, heat-inactivated, gamma-irradiated options) from certified EU donor centres. Full CoA per lot — viral screening, sterility, endotoxin, mycoplasma. No minimum order quantity.
View Human Serum Portfolio Request Documentation Package
English 
Deutsch